Lecture 24: Hormone Replacement Therapy Flashcards
Estrogen Actions: Desirable Effects
The Brain:
(3)
- Regulates area that prepares body for reproduction
- Helps maintain stable temperature and avoid hot flashes
- May help protect memory
Estrogen Actions: Desirable Effects
The Breasts:
Programs glands to produce milk
Estrogen Actions: Desirable Effects
The Liver and Heart:
(2)
- Helps regulate production of cholesterol in the liver
- helps avoid atherosclerosis and heart attacks
Estrogen Actions: Desirable Effects
The Uterus:
- Programs the uterus to nourish a fetus
Estrogen Actions: Desirable Effects
The Bones:
- Maintains density
Estrogen Actions: Undesirable Effects
The Breasts:
-Promotes breast cancer
Estrogen Actions: Undesirable Effects
The Uterus:
- Promotes cancer of the uterine lining
Pre-Menopause
Before menopause, ovaries produce:
- Estrogen
- Progesterone
Pre-Menopause
During years of ovarian estrogen production, women benefit from these activities:
(3)
- Protection against cardiovascular disease
- Estrogen prevents atherosclerotic lesion formation
- Prevents or reversal of bone loss (osteoporosis)
Menopause
Average age of menopause in US is:
51
Menopause
Common symptoms associated with estrogen deficiency are:
- Hot flashes
- Vaginal Atrophy
- Sleep Disturbance
Conjugated Equine Estrogen (CEE)
Premarin is a commercial name for a compound drug consisting primarily of conjugated estrogens for hormone therapy. It consists of
- Estrone (> 50%)
- Equilin (15-25%)
- Equilienin
Conjugated Equine Estrogen (CEE)
Estrogen are conjugated because:
- of it being hydrophilic side-groups attached
Conjugated Equine Estrogen (CEE)
Estrone sulfate is easily absorbed and converted to ______ by body
Estradiol
Conjugated Equine Estrogen (CEE)
Premarin is isolated from
Mare’s urine
Conjugated Equine Estrogen (CEE)
Prempro is CEE plus this; a synthetic Progesterone.
Medroxyprogesterone acetate (MPA)
Progestin helps reduce the risk of endometrial cancer by:
maintaining endometrial atrophy in women with uterus
CEE + MPA study was stopped in July 2002
This was because women taking CEE + MPA demonstrated health problems such as:
- increased risk of stroke
- increased risk of venous thromboembolic events
- increased risk of invasive breast cancer